Fluorocholine(18F) has a clinical usefulness in prostate cancer and in hepatocellular carcinoma... sometimes in the same patient;La fluorocholine(18F) a une utilité clinique dans le cancer de la prostate et le carcinome hépatocellulaire parfois chez le même malade

Medecine Nucleaire

Volumn 34, Issue 7, 2010, Pages 378-382

  Balogova, S ^a,b   Bumsel, F ^c   Kerrou, K ^a   Huchet, V ^a   Nataf, V ^a   Mal, F ^d   Gutman, F ^a   Montravers, F ^a   Talbot, J N ^a  

^a HÔPITAL TENON   (France)

^b Faculty of Natural Sciences   (Slovakia)

^c HÔPITAL SAINT ANTOINE   (France)

^d INSTITUT MUTUALISTE MONTSOURIS   (France)

Author keywords

Fluorocholine(18F); Fluorodeoxyglucose(18F); Hepatocellular carcinoma; PET CT; Pulmonary nodule; Recurrent prostate cancer

Indexed keywords

BICALUTAMIDE; CHOLINE; FLUOROCHOLINE F 18; SORAFENIB; TRIPTORELIN; UNCLASSIFIED DRUG;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; CANCER STAGING; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIAGNOSTIC VALUE; HUMAN; LIVER CELL CARCINOMA; LUNG METASTASIS; LUNG NODULE; MALE; PROSTATE CANCER;

EID: 77954834103     PISSN: 09281258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mednuc.2010.05.007     Document Type: Article

References (15)

1. De Grado T.R., Baldwin S.W., Wang S., Orr M.D., Liaoo R.P., et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001, 42:1805-1814.
2. Talbot J.N., Gutman F., Huchet V., Kerrou K., Balogova S., Kerrouche N., et al. Utilité clinique de la tomographie par émission de positons dans le cancer de la prostate. Presse Med 2007, 36(12 Pt 2):1794-1806.
3. Bourget P et le groupe de travail SOR. Utilisation de la TEP-FDG dans les cancers digestifs. Bulletin de synthèse de veille. 2006. Epub: http://www.fnclcc.fr/fr/sor.
4. Talbot J.N., Gutman F., Fartoux L., Grange J.D., Ganne N., et al. PET/CT in patients with hepatocellular carcinoma using [18F]fluorocholine: preliminary comparison with [18F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006, 33:1285-1289.
5. Balogova S., Huchet V., Gutman F., Kerrou K., Nataf V., Montravers F., et al. Fluoromethylcholine (18F) PET/CT for the detection of hepatocellular carcinoma in patients with a chronic liver disease and liver nodules: prospective comparison with FDG (18F) PET/CT. Eur J Nucl Med Mol Imaging 2009, 36. S177-OP101.
6. Cimitan M., Bortolus R., Morassut S., Canzonieri V., Garbeglio A., Baresic T., et al. [18F]fluorocholine PET/CT imaging for the detection of recurrent prostate cancer at PSA relapse: experience in 100 consecutive patients. Eur J Nucl Med Mol Imaging 2006, 33:1387-1398.
7. Kwee S.A., DeGrado T.R., Talbot J.N., Gutman F., Coel M.N., et al. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 2007, 37:420-428.
8. Pelosi E., Arena V., Skanjeti A., Pirro V., Douroukas A., Pupi A., et al. Role of whole-body 18F-choline PET/CT in disease detection in patients with biochemical relapse after radical treatment for prostate cancer. Radiol Med 2008, 113:895-904.
9. Hess K.R., Varadhachary G.R., Taylor S.H., Wei W., Raber M.N., Lenzi R., et al. Metastatic patterns in adenocarcinoma. Cancer 2006, 106:1624-1633.
10. Leibovici D., Spiess P.E., Agarwal P.K., Tu S.M., Pettaway C.A., Hitzhusen K., et al. Prostate cancer progression in the presence of undetectable or low serum prostate-specific antigen level. Cancer 2007, 109:198-204.
11. Balogova S., Huchet V., Kerrou K., Nataf V., Gutman F., Antoine M., et al. Detection of bronchioloalveolar cancer by means of PET/CT and 18F-fluorocholine, and comparison with 18F-fluorodeoxyglucose. Nucl Med Commun 2010, 31:389-397.
12. Yossepowitch O., Bianco F.J., Eggenera S.E., Eastham J.A., Scher H.I., Scardino P.T. The natural history of noncastrate metastatic prostate cancer after radical prostatectomy. Eur Urol 2007, 51:940-948.
13. Hara T., Kondo T., Hara T., Kosaka N. Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 2003, 99:474-479.
14. Kwee S.A., Ko J.P., Jiang C.S., Watters M.R., Coel M.N. Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology 2007, 244:557-565.
15. Schillaci O., Calabria F., Tavolozza M., Cicciò C., Carlani M., Caracciolo C.R., et al. 18F-choline PET/CT physiological distribution and pitfalls in image interpretation: experience in 80 patients with prostate cancer. Nucl Med Commun 2010, 31:39-45.